EU approves remedies package required to clear Lufthansa's ITA deal
BRUSSELS, Nov 29 (Reuters) -The European Commission said on Friday that it had approved EasyJet, IAG and Air France-KLM as the takers of remedies required for Lufthansa's planned purchase of a minority stake in Italy's ITA Airways.
Lufthansa won EU antitrust approval in July to buy 41% of state-owned ITA, the successor airline to bankrupt Alitalia, for 325 million euros ($343.6 million), in a deal designed to boost its presence in the lucrative southern European market.
However, Lufthansa and the Italian ministry of economy and finance had to make commitments to allow competitors to take up more short- and long-haul flights from Italy and transfer some take-off and landing slots at Milan's Linate Airport.
($1 = 0.9459 euros)
Reporting by Philip Blenkinsop
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
